<DOC>
	<DOCNO>NCT02425891</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind study evaluate efficacy , safety , pharmacokinetics atezolizumab ( MPDL3280A ) administer nab-paclitaxel compare placebo combination nab-paclitaxel participant locally advance metastatic triple-negative breast cancer ( TNBC ) receive prior systemic therapy metastatic breast cancer ( mBC ) . The safety single-agent nab-paclitaxel determine previous study participant mBC safety data date suggest atezolizumab safely combined standard chemotherapy agent .</brief_summary>
	<brief_title>A Study Atezolizumab Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer ( IMpassion130 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Metastatic locally advance , histologically document TNBC characterize absence human epidermal growth factor 2 ( HER2 ) , estrogen receptor ( ER ) , progesterone receptor ( PR ) expression No prior chemotherapy targeted systemic therapy inoperable locally advanced metastatic TNBC Eligible taxane monotherapy ( i.e. , absence rapid clinical progression , lifethreatening visceral metastasis , need rapid symptom and/or disease control ) A representative formalinfixed , paraffinembedded tumor specimen paraffin block , least 20 unstained slide associated pathology report document ER , PR , HER2 negativity . Participants few 20 unstained slide available baseline , few 12 unstained slide eligible upon discussion Medical Monitor Eastern Cooperative Oncology Group performance status 0 1 Measurable disease define RECIST v1.1 Adequate hematologic endorgan function Known central nervous system ( CNS ) disease , except treat asymptomatic CNS metastases Leptomeningeal disease Pregnancy lactation History autoimmune disease Prior allogeneic stem cell solid organ transplantation Positive test human immunodeficiency virus Active hepatitis B hepatitis C Receipt live , attenuated vaccine within 4 week prior randomization , treatment , within 5 month follow last dose atezolizumab/placebo</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>